Cargando…
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylas...
Autores principales: | Federico, Mario, Bagella, Luigi |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004414/ https://www.ncbi.nlm.nih.gov/pubmed/21188171 http://dx.doi.org/10.1155/2011/475641 |
Ejemplares similares
-
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
por: Ellis, Leigh, et al.
Publicado: (2010) -
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies
por: Imai, Yoichi, et al.
Publicado: (2016) -
Histone deacetylase inhibitors: clinical implications for hematological malignancies
por: Tambaro, Francesco Paolo, et al.
Publicado: (2010) -
Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies
por: Pal, Dilipkumar, et al.
Publicado: (2023) -
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)